jurgenfr
Emergent Biosolutions (NYSE:EBS) stock rose 14% post-market Wednesday after the company raised the lower end of its revenue guidance range and announced a study for its drug brincidofovir in the treatment of mpox.
After market close, the company reported Q3 non-GAAP